<DOC>
	<DOCNO>NCT02968563</DOCNO>
	<brief_summary>The objective study determine preliminary efficacy safety combination tirabrutinib ( GS-4059 ) idelalisib without obinutuzumab adult relapse refractory chronic lymphocytic leukemia ( CLL ) . The study 6 patient per arm safety run-in evaluate safety prior enrollment subsequent participant . The primary objective evaluation efficacy secondary objective evaluation safety evaluation additional parameter efficacy . The treatment period adaptive , duration active treatment two year total follow-up study 5 year time-dependent outcome variable .</brief_summary>
	<brief_title>Safety Efficacy Combination Tirabrutinib Idelalisib With Without Obinutuzumab Adults With Relapsed Refractory Chronic Lymphocytic Leukemia ( CLL )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<mesh_term>Idelalisib</mesh_term>
	<criteria>Key Documentation relapse refractory CLL Requiring treatment per modify IWCLL 2008 criterion AND radiographically measureable disease ( define ≥ 1 lesion &gt; 1.5 cm diameter assess compute tomography ( CT ) magnetic resonance imaging ( MRI ) ) Adequate hematologic function : platelet count ≥ 50 × 10^9/L , neutrophil count ≥ 1 × 10^9/L , hemoglobin ≥ 8 g/dL unless low value directly attributable document bone marrow burden CLL Creatinine clearance ( CrCl ) ≥ 50 mL/min Total bilirubin ≤ 1.5× institutional upper limit normal ( ULN ) unless attribute Gilbert 's syndrome aspartate transaminase ( AST ) /alanine transaminase ( ALT ) ≤ 2.5×ULN Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) ≤ 2 Absence active HIV , hepatitis B virus ( HBV ) infection , hepatitis C virus ( HCV ) infection , cytomegalovirus ( CMV ) infection Satisfies follow criterion : For female childbearing potential , willingness abstain sexual intercourse use protocolspecified method contraception describe study protocol Males reproductive potential engage sexual intercourse must agree use protocolspecified method ( ) contraception describe study protocol Able comply study procedure restriction include mandatory prophylaxis Pneumocystis jirovecii pneumonia ( PJP ) Key Known transformation CLL ( ie , Richter 's transformation , prolymphocytic leukemia ) Known central nervous system ( CNS ) involvement Prior therapy inhibitor Bruton 's tyrosine kinase ( BTK ) , spleen tyrosine kinase ( SYK ) , phosphatidylinositol 3kinase ( PI3K ) , Bcell lymphoma 2 ( BCL2 ) , obinutuzumab Any treatment CLL corticosteroids symptomatic management within 28 day start study treatment Participation concurrent therapeutic clinical trial unless treatment complete ongoing surveillance Diagnosis concern progressive multifocal leukoencephalopathy History myelodysplastic syndrome another malignancy CLL , except follow : malignancy complete remission 3 year , adequately treat local basal cell squamous cell carcinoma skin , cervical carcinoma situ , superficial bladder cancer , asymptomatic prostate cancer without know metastatic disease requirement therapy require hormonal therapy normal prostatespecific antigen ≥1 year prior start study therapy Active infection require systemic therapy Pregnant nursing woman ( negative pregnancy test require woman childbearing potential within 7 day start treatment monthly therapy ) Active autoimmune disease need high prednisone 10 mg daily unless management CLL symptom Treatment prophylaxis CMV within past 28 day History stroke intracranial hemorrhage within 12 month randomization ; subject require therapeutic anticoagulation indication discussed German CLL Study Group ( GCLLSG ) cooperate physician and/or medical monitor prior screening . Use strong CYP3A4 strong Pgp inducer within 2 week first dose study treatment anticipate chronic use study Demonstration correct QT ( QTc ) interval &gt; 450 millisecond requirement ongoing treatment concomitant medication prolong QT interval Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>